IMAAVYBeyond's analysis on IMAAVY2026-08-25 — FDA’s approval of IMAAVY provides the first-ever drug for warm autoimmune hemolytic anemia, creating a new niche in rare disease therapeuticsRecent news mentioning IMAAVY2026-09-29 — Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG)Browse the full archive →